CN110382490A - 喹唑啉类化合物及其制备方法、用途和药物组合物 - Google Patents

喹唑啉类化合物及其制备方法、用途和药物组合物 Download PDF

Info

Publication number
CN110382490A
CN110382490A CN201780075753.0A CN201780075753A CN110382490A CN 110382490 A CN110382490 A CN 110382490A CN 201780075753 A CN201780075753 A CN 201780075753A CN 110382490 A CN110382490 A CN 110382490A
Authority
CN
China
Prior art keywords
quinazoline compounds
purposes
preparation
pharmaceutical composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780075753.0A
Other languages
English (en)
Chinese (zh)
Inventor
许恒
陈晓光
林松文
季鸣
金晶
吴德雨
王春阳
吕元皓
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Materia Medica, CAMS&PUMC
Original Assignee
Institute of Materia Medica, CAMS&PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62707834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110382490(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN201611211589.5A external-priority patent/CN108239075B/zh
Priority claimed from CN201611214102.9A external-priority patent/CN108239076B/zh
Priority claimed from CN201611204309.8A external-priority patent/CN108239074B/zh
Application filed by Institute of Materia Medica, CAMS&PUMC filed Critical Institute of Materia Medica, CAMS&PUMC
Publication of CN110382490A publication Critical patent/CN110382490A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780075753.0A 2016-12-26 2017-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物 Pending CN110382490A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2016112043098 2016-12-26
CN201611211589.5A CN108239075B (zh) 2016-12-26 2016-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物
CN2016112115895 2016-12-26
CN201611214102.9A CN108239076B (zh) 2016-12-26 2016-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物
CN201611204309.8A CN108239074B (zh) 2016-12-26 2016-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物
CN2016112141029 2016-12-26
PCT/CN2017/118771 WO2018121550A1 (zh) 2016-12-26 2017-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物

Publications (1)

Publication Number Publication Date
CN110382490A true CN110382490A (zh) 2019-10-25

Family

ID=62707834

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780075753.0A Pending CN110382490A (zh) 2016-12-26 2017-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物

Country Status (7)

Country Link
US (3) US11534443B2 (cg-RX-API-DMAC7.html)
EP (3) EP4169918B8 (cg-RX-API-DMAC7.html)
JP (3) JP7077323B2 (cg-RX-API-DMAC7.html)
CN (1) CN110382490A (cg-RX-API-DMAC7.html)
AU (3) AU2017389818B2 (cg-RX-API-DMAC7.html)
CA (3) CA3048546A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018121550A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555588A (zh) * 2019-11-07 2022-05-27 南京正大天晴制药有限公司 作为axl抑制剂的喹唑啉类化合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4169918B8 (en) * 2016-12-26 2025-09-24 Institute of Materia Medica, Chinese Academy of Medical Sciences Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer
CN113620976B (zh) * 2020-05-09 2023-09-26 中国医学科学院药物研究所 噻唑并嘧啶类化合物及其制备方法、用途和药物组合物
PE20231311A1 (es) 2020-11-18 2023-08-24 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
MX2024006627A (es) 2021-12-03 2024-08-22 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos.
TW202416953A (zh) * 2022-08-26 2024-05-01 日商衛材R&D企管股份有限公司 抗體藥物複合物
CA3223670C (en) 2023-03-30 2026-05-26 Sunstack, Llc Trestle

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440408A (zh) * 2000-04-25 2003-09-03 艾科斯有限公司 人磷脂酰肌醇3-激酶δ的抑制剂
WO2008157191A2 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Quinazoline derivatives as pi3 kinase inhibitors
CN108239075A (zh) * 2016-12-26 2018-07-03 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
CN108239076A (zh) * 2016-12-26 2018-07-03 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
CN108239074A (zh) * 2016-12-26 2018-07-03 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960008781B1 (ko) * 1993-08-05 1996-07-03 김하운 연소효율 증강장치
TW200902008A (en) 2007-05-10 2009-01-16 Smithkline Beecham Corp Quinoxaline derivatives as PI3 kinase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体
CN105283454B (zh) * 2013-04-12 2019-10-29 阿萨纳生物科技有限责任公司 作为ras/raf/mek/erk和pi3k/akt/pten/mtor通路双重抑制剂的喹唑啉和氮杂喹唑啉
EP4169918B8 (en) * 2016-12-26 2025-09-24 Institute of Materia Medica, Chinese Academy of Medical Sciences Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440408A (zh) * 2000-04-25 2003-09-03 艾科斯有限公司 人磷脂酰肌醇3-激酶δ的抑制剂
WO2008157191A2 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Quinazoline derivatives as pi3 kinase inhibitors
CN108239075A (zh) * 2016-12-26 2018-07-03 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
CN108239076A (zh) * 2016-12-26 2018-07-03 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
CN108239074A (zh) * 2016-12-26 2018-07-03 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555588A (zh) * 2019-11-07 2022-05-27 南京正大天晴制药有限公司 作为axl抑制剂的喹唑啉类化合物
CN114555588B (zh) * 2019-11-07 2024-08-06 南京正大天晴制药有限公司 作为axl抑制剂的喹唑啉类化合物

Also Published As

Publication number Publication date
AU2017389818B2 (en) 2022-04-07
AU2022202885B2 (en) 2022-10-13
EP4169917A1 (en) 2023-04-26
CA3048546A1 (en) 2018-07-05
US11534443B2 (en) 2022-12-27
JP2022119853A (ja) 2022-08-17
EP3560921A1 (en) 2019-10-30
EP4169917B1 (en) 2025-07-30
EP4169918B1 (en) 2025-07-30
JP7384535B2 (ja) 2023-11-21
JP7384536B2 (ja) 2023-11-21
WO2018121550A1 (zh) 2018-07-05
JP7077323B2 (ja) 2022-05-30
EP3560921B1 (en) 2024-08-14
CA3174890A1 (en) 2018-07-05
AU2022202886B2 (en) 2023-04-13
US12508263B2 (en) 2025-12-30
JP2020503321A (ja) 2020-01-30
AU2022202885A1 (en) 2022-05-26
US20230113478A1 (en) 2023-04-13
US12508264B2 (en) 2025-12-30
US20210128559A1 (en) 2021-05-06
EP3560921A4 (en) 2020-07-29
US20230110550A1 (en) 2023-04-13
JP2022119852A (ja) 2022-08-17
EP4169918B8 (en) 2025-09-24
AU2017389818A1 (en) 2019-08-08
EP4169918A1 (en) 2023-04-26
AU2022202886A1 (en) 2022-05-26
CA3174865A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
CN112469713A (zh) 芳基磷氧化物类衍生物抑制剂、其制备方法和应用
CN111757878A (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN109311792A (zh) 苯醚类衍生物、及其制法和药物组合物与用途
CN110198943A (zh) 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
WO2017100726A8 (en) Methods for treating huntington's disease
WO2016172134A3 (en) Novel compounds
CN107995862B8 (zh) 包含sglt-2抑制剂之液态药物组合物
CN110139865A (zh) Fgfr抑制剂
CN110072865A (zh) 吡咯并芳杂环类化合物及其制备方法和医药用途
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CN110121502A (zh) 一种抗抑郁化合物及其制备方法和应用
CN113906026A (zh) 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN112543755A (zh) 一类细胞坏死抑制剂及其制备方法和用途
BR112014029709A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença mediados por uma fgfr cinase
MA40283A (fr) Aptamères spécifiques du récepteur tlr-4 et leurs utilisations
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
CN109863160A (zh) 核苷磷酸类化合物及其制备方法和用途
CN112119070A (zh) 选择性jak2抑制剂及其应用
CN109415361A (zh) 丙烯酸类衍生物及其制备方法和其在医药上的用途
WO2016102672A3 (en) Inhibitors of akt kinase
CN109641897A (zh) Bcl-2选择性抑制剂及其制备和用途
WO2017134685A3 (en) Novel hydrazino compounds as btk inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191025

WD01 Invention patent application deemed withdrawn after publication